Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia

Bibliography

• Fonesca F, Ruiz A, Cardona-Mu–oz E: The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value– an Evaluation of Rosuvastatin Therapy Compared with Atorvastatin. Curr. Med. Res. Opin. 21(8), 1307–1315 (2005).
   Google Scholar
• McKenney J, Jones P, Adamczyk M et al.: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: resultsfrom the STELLAR trial. Curr. Med. Res.Opin. 19(9), 689–698 (2003).
   Google Scholar
• Meyer J, Schultz J, O–Donnell J, Patel P, Sasane R: Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health. 8, 601–612(2005).
   Google Scholar
• Foley K, Simpson R Jr, Crouse J 3rd et al.: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol. 92, 79–81 (2003).
   Google Scholar
• Schuster H: Improving lipid management – to titrate, combine or switch. Int. J. Clin. Pract. 58(7), 689–694 (2004).
   Google Scholar
• Pearson T, Laurora I, Chu H, Kafoneck S: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459–467 (2000).
   Google Scholar
• Liberopoulos E, Florentin M, Mikhailidis D, Elisaf M: Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin. Drug Saf. 7(6), 717–725 (2008).
   Google Scholar
• Bortorff C, Houri J, Natarbartolo A et al.: Statin safety: what to know. Am. J. Geriatr. Cardiol. 13(3 Suppl. 1), 34–38 (2004).
   Google Scholar
• de Lemos J, Blazing M, Wiviott S et al.: Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307–1316 (2004).
   Google Scholar
• Waters D: Safety of high-dose atorvastatin therapy. Am. J. Cardiol. 96(5A), F69–F75 (2005).
   Google Scholar
• Shitara Y, Sato H, Sugiyama Y: Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689–723 (2005).
   Google Scholar
• Rutishauser J: The role of statins in clinical medicine– LDL-cholesterol lowering and beyond. Swiss Med. Wkly 136(3–4), 41–49 (2006).
   Google Scholar
• Ansell B: Not getting to goal: the clinical costs of noncompliance. J. Manag. Care Pharm. 14(Suppl. 6B), 9–15 (2008).
   Google Scholar
• Watson K: What is the evidence in favor of low-dose statin therapy in 2008? Curr. Atheroscler. Rep. 10(1), 33–38 (2008).
   Google Scholar
• Murphy M, Wei L, Watson A, MacDonald T: –Real-life– reduction in cholesterol with statins, 1993 to 2002. Br. J. Clin. Pharmacol. 65(4), 587–592 (2008).
   Google Scholar
• Stein E: Managing dyslipidemia in the high-risk patient. Am. J. Cardiol. 89, C50–C57 (2002).
   Google Scholar
• Isley W: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today 37, 587–594 (2001).
   Google Scholar
• Hayashi T, Yokote K, Saito Y, Iguchi A: Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin. Pharmacother. 8, 2315–2327 (2007).
   Google Scholar
• Fujino H, Yamada I, Kojima J et al.: Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and humans. Xenobio. Metabol. Dispos. 14, 415–424 (1999).
   Google Scholar
• Fuijno H, Saito T, Tsunenari Y, Kojima J: Interaction between several medicines and statins. Arzneimittelforschung 53(3), 145–153 (2003).
   Google Scholar
• Sakaeda T, Fujino H, Komoto C: Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYPmediated metabolism and MDR1 mediated transport. Pharm. Res. 23, 506–512 (2006).
   Google Scholar
• Hirano M, Maeda K, Shitara Y: Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229–1236 (2006).
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106, 3143–3421 (2002).
   Google Scholar
• European Atherosclerosis Society: The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 9, 571–600 (1988).
   Google Scholar
• Noji Y, Higashikata T, Inazu A et al.: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163, 157–164 (2002).
   Google Scholar
• Kajinami K, Koizumi J, Ueda K et al.: Effects of NK-104, a new hydroxymethylglutarylcoenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia: Hokuriku NK-104 Study Group. Am. J. Cardiol. 85, 178–183 (2000).
   Google Scholar
• Strandberg T, Feely J, Sigurdsson E: Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin. Ther. 26(11), 1821–1833 (2004).
   Google Scholar
• Yoshitomi Y, Ishii T, Kaneki M et al.: Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J. Atheroscler. Thromb. 13(2), 108–113 (2006).
   Google Scholar
• Park S, Kang H-J, Rim S-J: A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients withhypercholesterolemia. Clin. Ther. 27,1074–1082 (2005).
   Google Scholar
• Friedewald W, Levy D, Fredrickson D: Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972).
   Google Scholar
• LaRosa J, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled studies. JAMA 282, 2340–2346 (1999).
   Google Scholar
• Heart Protection Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled study. Lancet 360(9326), 7–22 (2002).
   Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T et al.: A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30, 1089–1101 (2008).
   Google Scholar
• Grigioni F, Carigi S, Potena L et al.: Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc. 38(5), 1507–1510 (2006).
   Google Scholar
• Versmissen J, Oosterveer D, Yazdanpanah M et al.: Efficacy of statins in familial hypercholesterolemia: a long-term cohort study. BMJ 337, a2423 (2008).
   Google Scholar
• Ratz Bravo A, Tchambaz L, Krhenb–hl- Melcher A et al.: Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 28(3), 263–275 (2005).
   Google Scholar
• Sanossian N, Ovbiagele B: Drug insight: translating evidence on statin therapy into clinical benefits. Nat. Clin. Pract. Neurol. 4(1), 42–49 (2008).
   Google Scholar
• Colleran K, Richards A, Shafer K: Disparities in cardiovascular disease risk and treatment: demographic comparison. J. Investig. Med. 55(8), 415–422 (2007).
   Google Scholar
• Jacobson T: Overcoming–ageism– bias in the treatment of hypercholesterolemia: a review of safety issues with statins in the elderly. DrugSaf. 29(5), 421–448 (2006).
   Google Scholar
• Gotto A: Statin therapy and the elderly: SAGE advice? Circulation 115, 681–683(2007).
   Google Scholar
• Cauley J, McTiernan A, Roadbough R et al.: Statin use and breast cancer: prospective results from the Women–s Health Initiative. J. Natl Cancer Inst. 98(10), 700–707 (2006).
   Google Scholar
• Kurihara Y, Douzono T, Kawakita K, Nagasaka Y: A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo– Tablet): LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol. Ther. 36(8), 709–731 (2008).
   Google Scholar
• Joint Formulary Committee: British MedicalAssociation and Royal Pharmaceutical Society of Great Britain. British National Formulary 50, 135 (2005).
   Google Scholar
• Jones P, Davidson M, Stein E et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 92, 152–160 (2003).
   Google Scholar
• Brown B, Stukovsky K, Zhao X: Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17, 631–636 (2006).
   Google Scholar
• Cardenas G, Lavie C, Cardenas V, Milani R, McCullough P: The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev. Cardiovasc. Med. 9(4), 239–258 (2008).
   Google Scholar
• Eypasch E, Lefering R, Kum CK, Troidl H: Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 311, 619–620 (1995).
   Google Scholar
• Black D, Bakker-Arkema R, Nawrocki J: An overview of the clinical safety profile of atorvastatin (LipitorTM), a new HMG-CoA reductase inhibitor Arch. Intern. Med. 158, 577–584 (1998).A
   Google Scholar